About GreenLight Biosciences
GreenLight Biosciences is a publicly listed company based in Lexington (United States) founded in 2008 by Andrey Zarur. RNA-based platform for life sciences is developed by GreenLight Biosciences. GreenLight Biosciences has raised $225.05 million across 13 funding rounds from investors including ARE, United States Department of Agriculture and Khosla Ventures. The company has 172 employees. GreenLight Biosciences was last valued at $1.2 billion in August 2021. Its chief executive, as recorded, is Andrey Zarur. GreenLight Biosciences offers products and services including Calantha and Norroa. Its focus areas include Life Sciences, Genomics, Applied Genomics and Multiple Application Areas. Its legal entity is GreenLight Biosciences, Inc. Its competitors include Veritas Genetics, Kailos and ARCpoint Labs; 2 of its 3 listed competitors have raised funding.
Company details
GreenLight Biosciences was founded in 2008 and is based in Lexington, United States. A platform for RNA-based products is provided for the life science industry. Applications include vaccine development, antibody therapies, pandemic preparation, crop management, plant protection, and support for bee and pollinator health. Operations focus on biotechnology solutions across agriculture and human health sectors.
- Headquarters Lexington, United States
- Employees 172
- Founders Andrey Zarur
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website greenlightbiosciences.com
- Social LinkedIn X
- Legal Name Greenlight Biosciences, Inc.
- Annual Revenue$6.78 M (USD)325as on Dec 31, 2022
- Net Profit-$167.06 M (USD)as on Dec 31, 2022
- EBITDA-$159.8 M (USD)as on Dec 31, 2022
- Total Equity Funding$225.05M (USD)
in 13 rounds
- Latest Funding Round$25M (USD), Post-IPO
Apr 2025
- InvestorsARE
& 38 more
- Employee Count172
Products & Services of GreenLight Biosciences
GreenLight Biosciences offers a comprehensive portfolio of products and services, including Calantha and Norroa.
Controls Colorado Potato Beetles in potato crops effectively and sustainably.
Protects honey bees from Varroa destructor mites through RNA-based solutions.
Funding Insights of GreenLight Biosciences
GreenLight Biosciences has successfully raised a total of $225.05M across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $225.05M
- Total Rounds 13
- Last Round Post-IPO — $25M
- First Round $31,942
(Dec 2009)
- Investors Count 39
Latest 10 of 13 funding rounds of GreenLight Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2025 | $25M | Post-IPO | – | – | |
| Jul 2024 | $174,350 | Grant | – | – | |
| Mar 2024 | $325,127 | Grant | – | – | |
| Aug 2022 | $109M | Post-IPO | – | – | |
| Nov 2021 | $10M | Series D | – | – | |
| Jun 2020 | $102M | Series D | – | Morningside | |
| May 2020 | $17M | Series D | – | Flu Lab, Xeraya Capital | – |
| Jan 2019 | $50M | Series D | – | S2G Ventures, Baird Capital | |
| Sep 2017 | $18M | Series D | – | Fall Line Capital | |
| Jun 2015 | $20.01M | Series C | – | Malaysian Life Sciences Capital Fund |
| Date | Valuation | Stage |
|---|
Full valuation and stage history of GreenLight Biosciences
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $1.2B (Aug 2021). 39 investors in total: 39 institutional.
Investors in GreenLight Biosciences
GreenLight Biosciences has secured backing from 39 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, United States Department of Agriculture and Khosla Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Stage agnostic venture capital firm | s2gventures.com | Chicago, United States | ||
Investments are directed to food, agribusiness, and commodities sectors. | continentalgrain.com | New York, United States | ||
VC firm that does early stage investments in the US | fall-line-capital.com | San Mateo, United States | ||
Multiple sectors are invested in by Morningside, a VC fund. | morningside.com | Newton, United States | ||
Investments in technology-based startups are made by Rivas Capital. | rivascap.com | Cambridge, United States | ||
Venture capital firm focused on multiple sectors | taocap.com | Marlborough, United States | ||
Early-stage venture capital is invested across sectors in US geographies. | mlscf.com | Kuala Lumpur, Malaysia | ||
Venture capital investments are directed toward agriculture and food sectors. | lewisandclarkagrifood.com | St. Louis, United States | ||
Limited information available | lupasystems.com | New York, United States | ||
Global private equity and venture capital investments in B2B Tech & Services companies. | bairdcapital.com |
Investor details for GreenLight Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GreenLight Biosciences
23 people are tracked at GreenLight Biosciences (14 in leadership, 9 in team); the tracked headcount is 172.
| Name | Role | Group |
|---|---|---|
Andrey Zarur | Co-Founder & CEO | Leadership |
Ray Farmer | Principal Scientist, Head Of Strain Engineering | Leadership |
Rohan Anderson | Associate Director, GMP Manufacturing, Human Health ‑ CMC Clinical Manufacturing | Leadership |
Gina Lambiase | Head Of Finance | Leadership |
Steven Victor Turbes | Senior Vice President Of Sales & Marketing | Leadership |
Catie Lee | Vp, BU Head - Bee & Animal Health | Leadership |
Mark Singleton | Chief Commercial Officer And General Manager | Leadership |
Katie Letheren | Director Of International Commercial Operations | Leadership |
Jacob Deguire | Vice President, People And Operations | Leadership |
Cameron Gibb | Vice President, Quality And Manufacturing R&d | Leadership |
Stephen Kaba | Director, Mrna-based Antigen Design, Vaccine Research | Leadership |
Ron Flannagan | Vice President Of Research, Plant Health | Leadership |
Narendran Sekar | Senior Scientist, Head Of Process Development | Leadership |
Ken Narva | Head Of Entomology, Research Fellow | Leadership |
Martin Waters | Senior Process Technician | Team |
Toni Villagran | Research Agronomist / Farm Operations Manager | Team |
Kendrya Cook | Manufacturing Systems Manager | Team |
Katie S. | Global Sample Logistics Lead | Team |
Rafael Jordán Ramírez | Agricultural Research Station Manager | Team |
Michael A Cantone | Finance Manager | Team |
3 more people are available in the full profile.
Complete people profiles for GreenLight Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of GreenLight Biosciences
5 dated milestones of GreenLight Biosciences across 17 years, from founding to its latest funding, stage changes and deals.
- Founded GreenLight Biosciences is founded.
- Funding First funding round of $32K.
- Milestone Reaches Unicorn status.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $25.0M.
Competitors of GreenLight Biosciences
GreenLight Biosciences has 3 listed competitors in our database, 2 of them funded. They include Veritas Genetics, Kailos and ARCpoint Labs.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| veritasgenetics.com | 2014 | Danvers, United States | $53.38M | 14 | Genetic testing products for health risks and traits are offered. | |
| kailosgenetics.com | 2010 | Huntsville, United States | $3.9M | 10 | Provider of consumer-based genetic testing services | |
| arcpointlabs.com | 2005 | Greenville, United States | Provider of genetic testing services |
Detailed competitors of GreenLight Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of GreenLight Biosciences
The website of GreenLight Biosciences (greenlightbiosciences.com) receives about 6K visits a month.
- Monthly visits6K
▼ 18.3% vs previous month
Websites whose visitors overlap most with GreenLight Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| greenlight.ai | 100% | 14.6K | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as GreenLight Biosciences (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Greenlight Biosciences
Complete news archive for GreenLight Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GreenLight Biosciences
GreenLight Biosciences was founded in 2008 and raised its 1st funding round 1 year after it was founded.
GreenLight Biosciences is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Andrey Zarur is the CEO of GreenLight Biosciences, as recorded in our data. They have also founded this company.
GreenLight Biosciences is a funded company, having raised a total of $225.05M across 13 funding rounds to date. The company's 1st funding round was a Series C of $20.01M, raised on Dec 2009.
GreenLight Biosciences has 172 employees.
Annual revenue of GreenLight Biosciences is $6.78M as on Dec 31, 2022.
GreenLight Biosciences was founded in 2008 and is based in Lexington, United States. A platform for RNA-based products is provided for the life science industry. Applications include vaccine development, antibody therapies, pandemic preparation, crop management, plant protection, and support for bee and pollinator health. Operations focus on biotechnology solutions across agriculture and human health sectors.
GreenLight Biosciences's top competitors include Veritas Genetics, ARCpoint Labs and Kailos.
GreenLight Biosciences offers Calantha and Norroa.
GreenLight Biosciences has 39 investors. Key investors include ARE, United States Department of Agriculture, Khosla Ventures, BNP Paribas Asset Management, and Greenlight Re.
The valuation of GreenLight Biosciences is $1.2B as of Aug 2021.
GreenLight Biosciences operates through Greenlight Biosciences, Inc..